AP2006003618A0 - Nucleic acids specifically binding bioactive ghrelin - Google Patents

Nucleic acids specifically binding bioactive ghrelin

Info

Publication number: AP2006003618A0
Authority: AP; ARIPO
Prior art keywords: nucleic acids; specifically binding; acids specifically; bioactive ghrelin; binding bioactive
Prior art date: 2003-11-10

Application number

AP2006003618A

Other languages

English (en)

Inventor

Sven Klussmann

Dirk Eulberg

Christian Maasch

Original Assignee

Noxxon Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-10

Filing date

2004-11-10

Publication date

2006-06-30

2004-11-10 Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag

2006-06-30 Publication of AP2006003618A0 publication Critical patent/AP2006003618A0/xx

Links

102000012004 Ghrelin Human genes 0.000 title 1
101800001586 Ghrelin Proteins 0.000 title 1
230000000975 bioactive effect Effects 0.000 title 1
GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Hematology (AREA)
Analytical Chemistry (AREA)
Plant Pathology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)

AP2006003618A 2003-11-10 2004-11-10 Nucleic acids specifically binding bioactive ghrelin AP2006003618A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03025743		2003-11-10
PCT/EP2004/012739 WO2005049828A1 (fr)	2003-11-10	2004-11-10	Acides nucleiques se liant specifiquement a une ghreline bioactive

Publications (1)

Publication Number	Publication Date
AP2006003618A0 true AP2006003618A0 (en)	2006-06-30

Family

ID=34610046

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2006003618A AP2006003618A0 (en)	2003-11-10	2004-11-10	Nucleic acids specifically binding bioactive ghrelin

Country Status (19)

Country	Link
US (2)	US20070031840A1 (fr)
EP (1)	EP1682662A1 (fr)
JP (1)	JP4823067B2 (fr)
KR (1)	KR20060125743A (fr)
CN (1)	CN1894407A (fr)
AP (1)	AP2006003618A0 (fr)
AU (1)	AU2004291656A1 (fr)
BR (1)	BRPI0415872A (fr)
CA (1)	CA2544805A1 (fr)
CR (1)	CR8388A (fr)
EA (1)	EA009376B1 (fr)
EC (1)	ECSP066559A (fr)
IL (1)	IL175443A0 (fr)
MA (1)	MA28153A1 (fr)
NO (1)	NO20062663L (fr)
OA (1)	OA13282A (fr)
TN (1)	TNSN06132A1 (fr)
WO (1)	WO2005049828A1 (fr)
ZA (1)	ZA200603435B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1530635B1 (fr) *	2002-08-01	2011-06-15	Noxxon Pharma AG	Acides nucleiques a liaison de ghreline
EP2290073A3 (fr) *	2004-05-28	2011-08-31	Asuragen, Inc.	Procédés et compositions impliquant du microARN
EP2302055B1 (fr)	2004-11-12	2014-08-27	Asuragen, Inc.	Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
UY29460A1 (es)	2005-04-08	2006-11-30	Noxxon Pharma Ag	Acidos nucleicos de union a ghrelin
US20090131348A1 (en) *	2006-09-19	2009-05-21	Emmanuel Labourier	Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008036776A2 (fr) *	2006-09-19	2008-03-27	Asuragen, Inc.	Gènes régulés mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention thérapeutique
AU2007333107A1 (en) *	2006-12-08	2008-06-19	Asuragen, Inc.	miR-21 regulated genes and pathways as targets for therapeutic intervention
AU2007333109A1 (en) *	2006-12-08	2008-06-19	Asuragen, Inc.	Functions and targets of let-7 micro RNAs
WO2008073915A2 (fr) *	2006-12-08	2008-06-19	Asuragen, Inc.	Microarn exprimés de manière différentielle en cas de leucémie et leurs utilisations
CA2671270A1 (fr) *	2006-12-29	2008-07-17	Asuragen, Inc.	Genes et voies regules par mir-16 utiles comme cibles pour intervention therapeutique
US20090232893A1 (en) *	2007-05-22	2009-09-17	Bader Andreas G	miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) *	2007-05-22	2009-05-21	Bader Andreas G	miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2008261951A1 (en) *	2007-06-08	2008-12-18	Asuragen, Inc.	miR-34 regulated genes and pathways as targets for therapeutic intervention
WO2009036332A1 (fr)	2007-09-14	2009-03-19	Asuragen, Inc.	Microarn exprimés de manière différentielle dans le cancer du col de l'utérus et leurs utilisations
WO2009052386A1 (fr) *	2007-10-18	2009-04-23	Asuragen, Inc.	Micro arn exprimés différentiellement dans des maladies pulmonaires et leurs utilisations
WO2009070805A2 (fr) *	2007-12-01	2009-06-04	Asuragen, Inc.	Gènes régulés par le mir-124 et cheminements servant de cibles pour une intervention thérapeutique
WO2009086156A2 (fr) *	2007-12-21	2009-07-09	Asuragen, Inc.	Gènes et voies régulés par mir-10 servant de cibles dans le cadre d'une intervention thérapeutique
EP2260110B1 (fr) *	2008-02-08	2014-11-12	Asuragen, INC.	Micro arn (mirna) exprimés différentiellement dans des noeuds lymphoïdes prélevés chez des patients atteints d'un cancer
WO2009111643A2 (fr) *	2008-03-06	2009-09-11	Asuragen, Inc.	Marqueurs microrna pour la récurrence d’un cancer colorectal
EP2271757A2 (fr) *	2008-03-26	2011-01-12	Asuragen, INC.	Compositions et procédés liés à mir-16 et à la thérapie contre le cancer de la prostate
WO2009137807A2 (fr)	2008-05-08	2009-11-12	Asuragen, Inc.	Compositions et procédés liés à la modulation de miarn de néovascularisation ou d’angiogenèse
WO2010056737A2 (fr) *	2008-11-11	2010-05-20	Mirna Therapeutics, Inc.	Procédés et compositions impliquant des miarn dans des cellules souches cancéreuses
EP2493910A1 (fr)	2009-10-30	2012-09-05	Tranzyme Pharma, Inc.	Antagonistes et agonistes inverses macrocycliques du récepteur de la ghréline et leurs méthodes d'utilisation
US9976145B2 (en)	2011-01-10	2018-05-22	Noxxon Pharma Ag	Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
WO2013040251A2 (fr)	2011-09-13	2013-03-21	Asurgen, Inc.	Méthodes et compositions incluant mir-135b, permettant de faire la distinction entre un cancer du pancréas et une maladie pancréatique bénigne

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614395A (en) *	1988-03-08	1997-03-25	Ciba-Geigy Corporation	Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
ES2259800T3 (es) *	1990-06-11	2006-10-16	Gilead Sciences, Inc.	Procedimientos de uso de ligandos de acido nucleico.
US5780221A (en) *	1995-05-03	1998-07-14	Whitehead Institute For Biomedical Research	Identification of enantiomeric ligands
CA2218083A1 (fr) *	1995-05-03	1996-11-07	Antonius Nicolaas Maria Schumacher	Identification de enantiomeres
EP1286697A2 (fr) *	2000-05-17	2003-03-05	Eli Lilly And Company	Procede d'inhibition selective de la ghreline
US20030211967A1 (en) *	2001-05-07	2003-11-13	Bryant Henry Uhlman	Method for selectively inhibiting ghrelin action
US6967237B2 (en) *	2000-05-30	2005-11-22	Merck & Co., Inc.	Ghrelin analogs
EP1530635B1 (fr) *	2002-08-01	2011-06-15	Noxxon Pharma AG	Acides nucleiques a liaison de ghreline
UY29460A1 (es) *	2005-04-08	2006-11-30	Noxxon Pharma Ag	Acidos nucleicos de union a ghrelin

2004
- 2004-11-10 OA OA1200600147A patent/OA13282A/en unknown
- 2004-11-10 AP AP2006003618A patent/AP2006003618A0/xx unknown
- 2004-11-10 KR KR1020067009024A patent/KR20060125743A/ko not_active Withdrawn
- 2004-11-10 JP JP2006538786A patent/JP4823067B2/ja not_active Expired - Fee Related
- 2004-11-10 US US10/578,938 patent/US20070031840A1/en not_active Abandoned
- 2004-11-10 WO PCT/EP2004/012739 patent/WO2005049828A1/fr not_active Ceased
- 2004-11-10 CN CNA2004800377977A patent/CN1894407A/zh active Pending
- 2004-11-10 BR BRPI0415872-5A patent/BRPI0415872A/pt not_active IP Right Cessation
- 2004-11-10 AU AU2004291656A patent/AU2004291656A1/en not_active Abandoned
- 2004-11-10 EP EP04797787A patent/EP1682662A1/fr not_active Ceased
- 2004-11-10 CA CA002544805A patent/CA2544805A1/fr not_active Abandoned
- 2004-11-10 EA EA200600735A patent/EA009376B1/ru not_active IP Right Cessation
2006
- 2006-05-02 ZA ZA200603435A patent/ZA200603435B/en unknown
- 2006-05-04 IL IL175443A patent/IL175443A0/en unknown
- 2006-05-09 TN TNP2006000132A patent/TNSN06132A1/fr unknown
- 2006-05-10 EC EC2006006559A patent/ECSP066559A/es unknown
- 2006-05-10 CR CR8388A patent/CR8388A/es not_active Application Discontinuation
- 2006-05-10 MA MA29015A patent/MA28153A1/fr unknown
- 2006-06-09 NO NO20062663A patent/NO20062663L/no not_active Application Discontinuation
2010
- 2010-02-24 US US12/711,415 patent/US20100261291A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ZA200603435B (en)	2007-06-27
US20100261291A1 (en)	2010-10-14
JP4823067B2 (ja)	2011-11-24
IL175443A0 (en)	2006-09-05
AU2004291656A1 (en)	2005-06-02
KR20060125743A (ko)	2006-12-06
NO20062663L (no)	2006-08-09
EA009376B1 (ru)	2007-12-28
CA2544805A1 (fr)	2005-06-02
OA13282A (en)	2007-01-31
JP2007513608A (ja)	2007-05-31
ECSP066559A (fr)	2006-11-24
CR8388A (es)	2006-10-17
CN1894407A (zh)	2007-01-10
EA200600735A1 (ru)	2006-10-27
MA28153A1 (fr)	2006-09-01
BRPI0415872A (pt)	2007-01-09
US20070031840A1 (en)	2007-02-08
EP1682662A1 (fr)	2006-07-26
TNSN06132A1 (fr)	2007-11-15
WO2005049828A1 (fr)	2005-06-02

Publication	Publication Date	Title
IL175443A0 (en)	2006-09-05	Nucleic acids specifically binding bioactive ghrelin
IL186085A0 (en)	2008-01-20	Ghrelin binding nucleic acids
IL172617A0 (en)	2006-04-10	Biaryloxymethylarene-carboxylic acids
IL166376A0 (en)	2006-01-16	Immunostimulatory nucleic acids
EP1626981A4 (fr)	2006-11-22	Proteines protegees contre la dipeptidylpeptidase
AU2003239841A8 (en)	2003-11-17	Cgrp binding nucleic acids
IL181330A0 (en)	2007-07-04	Thiazolo-naphthyl acids
AU2003281867A8 (en)	2004-02-23	Antisense nucleic acids
EG23773A (en)	2007-08-08	Identification means
IL173150A0 (en)	2006-06-11	Improved inhibitor nucleic acids
GB0311423D0 (en)	2003-06-25	ID card
GB0218089D0 (en)	2002-09-11	Target DNA
GB0424460D0 (en)	2004-12-08	Launcher
AU2003304588A8 (en)	2005-06-24	Autotransporter
GB0313482D0 (en)	2003-07-16	Plastid proteins
AU156246S (en)	2004-08-23	Heater
AU156361S (en)	2004-09-07	Heater
AU156363S (en)	2004-09-07	Heater
AU156721S (en)	2004-10-21	Heater
AU156722S (en)	2004-10-21	Heater
AU157488S (en)	2005-02-03	Heater
AU157489S (en)	2005-02-03	Heater
GB0311675D0 (en)	2003-06-25	Heater
GB0320280D0 (en)	2003-10-01	Heater
AU156244S (en)	2004-08-23	Heater